Skip to main content

GLENBEX (Freyr Australia Pty Ltd)

Product name
GLENBEX
Date registered
Evaluation commenced
Decision date
Approval time
121 (255 working days
Active ingredients
betamethasone dipropionate, calcipotriol monohydrate
Registration type
New generic medicine
Indication

Topical treatment of psoriasis vulgaris in adults.

Registration process

First generic
First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine

Help us improve the Therapeutic Goods Administration site